Viking Therapeutics (VKTX) Misses Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Viking Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
July 27, 2022 4:05 PM EDTConference call scheduled for 4:30 p.m. ET today
Clinical Data From Three Programs Anticipated in Next Twelve MonthsVK2809 Phase 2b VOYAGE Study Advancing; Completion of Enrollment Expected in 4Q 2022Phase 1 Study of Dual GLP-1/GIP Agonist VK2735 Ongoing; Initial Results Expected by Year-EndPhase 1b Study of VK0214 in X-ALD to Resume; Results Expected in 1H 2023SAN DIEGO, July 27, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:... More
